Trust in the pharmaceutical industry takes another hit as Granules India embarks on the recall of over 33,000 bottles of blood pressure medication due to stability concerns.
See the tweet below!
Granules India, based in Hyderabad, is pulling 33,024 bottles of Metoprolol Succinate extended-release tablets from the US market.
This significant move was initiated on June 24 after stability testing failed due to “failed dissolution specifications.”
These specific tablets were manufactured in India and are distributed by Granules Pharmaceuticals Inc. in the US.
The fallout from this recall potentially affects millions who rely on consistent medication.
While the issue might sound technical, dissolution tests are crucial as they ensure the drug releases its active ingredient at the right rate.
Failing to meet these specifications could imply efficacy issues with the medication.
Fortunately, the USFDA has classified this recall as Class II, suggesting any risks are minimal and temporary or medically reversible.
The medication, in its 100-count and 500-count bottles, failed to meet dissolution criteria during the sixth-month stability studies.
While this might not result in severe adverse health effects, it’s enough to warrant a large-scale recall.
Such recall actions reflect the importance of stringent quality control in the pharmaceutical industry – a sector where precision and consistency can be life-saving.
“Granules India is recalling over 33,000 bottles of Metoprolol Succinate, a generic blood pressure medication, in the US due to manufacturing issues,” the FDA said.
For consumers, this means staying informed and cautious.
Patients using this medication are advised not to halt their treatment abruptly but to consult their healthcare providers.
The decision to recall demonstrates compliance with regulatory standards, which seeks to safeguard consumer trust and safety.
This event has also had a financial impact on the company, with shares of Granules India dropping slightly by 0.54% to Rs 479.10 on the Bombay Stock Exchange.
The US pharmaceutical market awaits further clarification and reassurance that such issues remain isolated and expertly managed to prevent future recurrence.
“the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal,” the FDA said further.
Hyderabad-based Granules recalls over 33,000 bottles of blood lowering medication#Granules #USFDA #Pharmaceutical #drugRecallhttps://t.co/rWkVwuOCQw
— Telangana Today (@TelanganaToday) July 9, 2025
